Cytotrait Ltd.
Biotechnology company providing plant organelle gene-editing technology.
Website: https://www.cytotrait.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Cytotrait Ltd. |
| Tagline | Biotechnology company providing plant organelle gene-editing technology |
| Headquarters | Manchester, UK |
| Founded | 2023 |
| Stage | Pre-Seed / Seed |
| Business Model | B2B |
| Industry | Agtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Dr. Junwei Ji (Co-Founder, Executive Director) |
| Funding Label | £3M Seed |
| Total Disclosed | ~$4.03M |
Links
PUBLIC
- Website: https://www.cytotrait.com
Executive Summary
PUBLIC
Cytotrait Ltd. is a University of Manchester biotechnology spinout developing organelle gene-editing tools for crops, a corner of agricultural biotech that has historically been hard to engineer at commercial scale [University of Manchester]. The company was founded in 2023 by Dr. Junwei Ji and in March 2026 closed a £3M (approximately $4.03M) seed round led by Northern Gritstone, with participation from the UK Innovation & Science Seed Fund [AgTechNavigator, March 2026]; [Tech.eu, March 2026]. Its core asset is the MOSS platform (Mutant Organelle Selection System), which the company says enables ultra-high trait expression by removing unedited copies of the chloroplast or mitochondrial genome so that edited copies propagate to homoplasmy, a long-standing bottleneck in organelle engineering [AgTechNavigator, March 2026]; [Tech Funding News]. The team has reported demonstrating the approach in two crops and is targeting wheat, maize, potato, and canola as initial commercial substrates [iGrow News, 2026]; [The Bae HQ, March 2026]. Northern Gritstone, a northern-England deep-tech investor anchored to the universities of Manchester, Leeds and Sheffield, also runs the NG Studios spinout program through which Cytotrait was incubated [Prolific North]. The business model is B2B, oriented toward licensing engineered traits or partnering with seed and trait developers rather than selling to farmers directly, although commercial structure has not been publicly detailed. Over the next 12 to 18 months, the most informative signals will be peer-reviewed validation of the MOSS mechanism, the first announced trait partnership with a major seed company, and progress through UK and EU gene-editing regulatory frameworks now being relaxed under the Precision Breeding Act.
Data Accuracy: GREEN -- Confirmed by AgTechNavigator (March 2026), University of Manchester, Tech.eu (March 2026), and Northern Gritstone press coverage in Prolific North.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed (£3M closed March 2026) |
| Business Model | B2B (trait licensing / partnership, inferred) |
| Industry / Vertical | Agtech, plant biotechnology |
| Technology Type | Organelle gene editing (chloroplast, mitochondrial) |
| Geography | Manchester, UK (Western Europe) |
| Growth Profile | Venture Scale, deep-tech |
| Founding Team | University of Manchester academic spinout |
| Funding | £3M / ~$4.03M disclosed |
Company Overview
PUBLIC
Cytotrait was incorporated in 2023 as a spinout from the University of Manchester, where the underlying organelle-editing research originated in Dr. Junwei Ji's laboratory [University of Manchester]; [Preqin]. The commercial vehicle was assembled with support from the University of Manchester Innovation Factory, the technology transfer arm responsible for translating university research into licensable companies, and from NG Studios, the venture studio operated by Northern Gritstone [University of Manchester Innovation Factory]; [Prolific North]. The legal entity is registered in England as Cytotrait Ltd., as confirmed by the company's own terms of use [Cytotrait].
The company spent its first roughly two years pre-seed, supported by undisclosed grant funding routed through the Innovation Factory, before closing its institutional seed round in early 2026 [University of Manchester Innovation Factory]; [Business Live]. The headline milestone to date is the £3M seed announced on 9 March 2026, reported across the UK technology and agtech press, with Northern Gritstone leading and the UK Innovation & Science Seed Fund (managed by Future Planet Capital) participating [Tech.eu, March 2026]; [Startupmag]. Coverage at the time of the round emphasised that the MOSS platform had been demonstrated in two crops, although the specific species pair was not named in the public materials [AgTechNavigator, March 2026].
Manchester is a deliberate location choice. The university hosts one of the larger UK plant science groupings, and Northern Gritstone, the lead investor, is structurally tied to commercialising research from the northern English university triangle. Cytotrait sits in a small but growing cohort of UK plant-biotech spinouts that have raised institutional seed capital since the 2023 passage of the Genetic Technology (Precision Breeding) Act, which created a lighter-touch regulatory pathway in England for precision-bred plants relative to the older GMO regime [The Bae HQ, March 2026].
Data Accuracy: GREEN -- Confirmed by University of Manchester, Cytotrait company terms, AgTechNavigator (March 2026), and Prolific North.
Product and Technology
MIXED
Cytotrait's product is a platform rather than a finished trait. The MOSS (Mutant Organelle Selection System) platform [PUBLIC] addresses a specific technical bottleneck in organelle engineering: plant cells contain many copies of the chloroplast and mitochondrial genomes per cell, and edits typically reach only a fraction of those copies, producing heteroplasmic plants in which the edited and unedited genomes coexist and the engineered trait is diluted or unstable [AgTechNavigator, March 2026]; [Tech Funding News]. According to the company's own description as carried in trade press, MOSS works by selectively removing the unedited genome copies so that edited copies can propagate to homoplasmy, the state in which every organelle genome in the cell carries the engineered change [AgTechNavigator, March 2026] [PUBLIC]. The company has stated the approach has been demonstrated in two crops, although the species and the underlying selection chemistry have not been disclosed publicly [AgTechNavigator, March 2026] [PUBLIC].
The stated commercial targets are staple field crops: wheat, maize, potato, and canola [iGrow News, 2026]; [The Bae HQ, March 2026] [PUBLIC]. These are deliberately ambitious. Chloroplast engineering at scale in monocots such as wheat and maize has been a long-standing unsolved problem in plant biotechnology, with most prior commercial chloroplast work confined to model dicots. The choice of substrates suggests Cytotrait is positioning MOSS as a horizontal enabler across both monocot and dicot row crops rather than a single-trait, single-species product. Reported applications include yield, stress tolerance, and trait stacking, framed by the founders as relevant to food security and sustainable agriculture [University of Manchester]; [International Biopharmaceutical Industry] [PUBLIC].
No public information is available on the company's IP estate beyond the implication that the foundational technology was licensed out of the University of Manchester via the Innovation Factory [University of Manchester Innovation Factory] [PUBLIC]. The company website is currently a minimal presence, restricted in public-facing content to a terms and privacy page, which is typical for a deep-tech spinout in its first commercial year [Cytotrait].
Data Accuracy: YELLOW -- Mechanism described consistently across AgTechNavigator, Tech Funding News, iGrow News and The Bae HQ, but no peer-reviewed publication or patent filing has been independently confirmed in the captured sources.
Market Research and Opportunity
PUBLIC
The market context for Cytotrait is the convergence of two cycles: a generational reset of crop trait development triggered by CRISPR and a regulatory thaw in major Western jurisdictions for precision-bred plants. Demand drivers are concrete. Climate stress on cereal yields, geopolitical pressure on fertilizer supply, and the unwinding of older glyphosate-tolerance trait packages have created appetite among seed companies for new trait sources, and the major incumbents (Bayer, Corteva, BASF, Syngenta) have publicly recommitted to gene-edited trait pipelines.
No independent third-party sizing for the organelle-editing sub-segment is available in the captured sources. As an analogous reference, the broader agricultural biotechnology and seed-trait market is established at multi-tens of billions of dollars annually, and CRISPR-based crop trait development is one of the more active investment categories in agtech, although Cytotrait's specific addressable slice depends on which traits its platform can credibly deliver into which crops. The captured coverage of the seed round consistently frames the opportunity around food security and yield resilience rather than a sized TAM [University of Manchester]; [International Biopharmaceutical Industry]; [Startupmag].
The regulatory tailwind is the most concrete near-term driver. The UK's Genetic Technology (Precision Breeding) Act, which received Royal Assent in 2023, creates a distinct and lighter regulatory class in England for plants produced by precision breeding techniques that could have arisen naturally or by traditional breeding. The European Union has been advancing a parallel proposal to create a category of New Genomic Techniques plants subject to lighter oversight than the existing GMO regime. For a UK-headquartered organelle-editing platform with stated ambitions across European row crops, the timing of these regulatory shifts is materially favorable relative to a 2018 or 2020 launch, when the EU Court of Justice's 2018 ruling kept gene-edited crops inside the full GMO framework.
Key adjacent and substitute markets include nuclear-genome CRISPR trait platforms (the dominant approach commercially today, used by companies such as Inari, Pairwise, and Tropic Biosciences), conventional and marker-assisted breeding (still the workhorse of the seed industry), and biological inputs such as microbial seed treatments that deliver trait-like outcomes without touching the plant genome. Organelle editing is differentiated within this set because chloroplasts can carry very high copy numbers of an engineered gene per cell, in principle enabling expression levels that nuclear transformation cannot reach, and because maternal inheritance of plastid genomes in many crops constrains pollen-mediated gene flow, a frequently cited regulatory and stewardship advantage.
| Sizing Reference | Value | Source |
|---|---|---|
| Cytotrait seed round, March 2026 | £3M / ~$4.03M | [AgTechNavigator, March 2026] |
| Stated initial crop targets | Wheat, maize, potato, canola | [iGrow News, 2026] |
| Crops with reported MOSS demonstration | 2 (species not named) | [AgTechNavigator, March 2026] |
The table above summarises what is independently verifiable today; the absence of a sized market figure is itself the analyst takeaway, in that investors at this stage are underwriting platform breadth and regulatory timing rather than a defined revenue pool.
Data Accuracy: YELLOW -- Round size and crop targets confirmed across multiple outlets; market sizing relies on category context rather than a named third-party report for the organelle-editing sub-segment specifically.
Competitive Landscape
MIXED
The captured sources do not name a direct competitor to Cytotrait, which is consistent with organelle-targeted crop editing being a thin commercial category, but it also means the competitive map must be drawn from the adjacent CRISPR crop-trait landscape rather than a head-to-head comparable.
The nearest segment is nuclear-genome CRISPR trait development for row crops, where the most visible private platforms are Inari Agriculture (US, multi-hundred-million-dollar funding to date, focused on seed design across corn, soy, and wheat) and Pairwise (US, partnership with Bayer for row-crop traits, consumer produce launches in leafy greens). Tropic Biosciences (UK) has built a CRISPR platform focused initially on tropical crops and has raised multiple institutional rounds. None of these is identified in Cytotrait's captured coverage, and the comparison is by category rather than by direct competitive overlap. A second adjacent segment is the chloroplast-engineering academic and small-company space, historically led by groups around Henry Daniell at the University of Pennsylvania and a small number of plastid-biotech startups; commercial activity here has been sparse, which is part of the structural opportunity Cytotrait is targeting. A third segment is the incumbent seed and trait majors (Bayer, Corteva, Syngenta, BASF) who are realistic future licensees or acquirers rather than near-term competitors at the platform layer.
Where Cytotrait can plausibly hold a defensible edge today is technical: if MOSS genuinely delivers reliable homoplasmy in monocots, that is a capability the broader chloroplast engineering field has been pursuing for two decades, and it would be patent-protectable and difficult to replicate without the underlying selection method. The university origin and Innovation Factory licensing structure suggest a clear IP chain, and Northern Gritstone's involvement provides a regional capital and follow-on bridge that is unusually deep for a UK plant-biotech seed. That edge is most exposed on two fronts. First, the much larger nuclear-CRISPR platforms can address many of the same end traits (yield, stress tolerance) without needing to solve the organelle problem at all, which means Cytotrait must compete on either expression level, regulatory profile (maternal inheritance), or specific traits that nuclear approaches cannot reach. Second, distribution into the seed channel is controlled by a very small number of multinationals; without a partnership announcement, the path from platform to commercial trait runs through gatekeepers Cytotrait does not yet own.
The most plausible 18-month competitive scenario splits into two named outcomes. Winner if MOSS is independently validated in wheat or maize and a top-four seed major signs even a non-exclusive evaluation deal: that single event would reprice the company against the broader CRISPR-trait comparable set and likely trigger a Series A at a meaningful step-up. Loser if homoplasmy in monocots proves to require crop-by-crop re-engineering rather than transferring as a platform: in that case the addressable footprint contracts toward dicot specialty crops and the company looks more like a single-trait developer than a horizontal platform, which is a materially harder venture-scale story.
Data Accuracy: ORANGE -- Cytotrait facts confirmed; competitor set inferred from category knowledge rather than named in captured sources.
Opportunity
PUBLIC
If MOSS works as described across multiple crops, Cytotrait is positioned to become the default organelle-editing layer for the global seed industry, a category that does not currently have a commercial standard-bearer.
The headline opportunity. The single largest outcome is platform status: MOSS becomes the licensed enabling technology that any seed company or trait developer uses when they want to engineer chloroplast or mitochondrial traits, in the same way certain Cas variants and delivery systems became default tooling in the nuclear CRISPR layer. The reason this outcome is reachable rather than aspirational is that the underlying technical problem (heteroplasmy in edited organelle genomes) is well-defined, widely acknowledged in the plant biology literature, and has resisted clean commercial solution for years. A platform that genuinely solves it, even in a subset of crops, has a natural licensing surface across every seed major and every specialty trait company [AgTechNavigator, March 2026]; [Tech Funding News].
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform licensor to seed majors | Cytotrait signs non-exclusive evaluation deals with two of Bayer / Corteva / Syngenta / BASF and converts one within 24 months | First peer-reviewed MOSS demonstration in wheat or maize | UK Precision Breeding Act and pending EU NGT framework lower the regulatory cost of evaluating new trait platforms [The Bae HQ, March 2026] |
| Vertical trait developer in a single high-value crop | Cytotrait keeps the platform proprietary and develops one or two flagship traits (e.g. nitrogen-use efficiency in canola) for direct licensing | Demonstrated yield or input-reduction data in field trials | Northern Gritstone's regional commitment supports a longer development arc than a typical seed-stage runway implies [Prolific North] |
| Acquisition by an incumbent | Strategic buyer absorbs the platform after Series A validation | Independent replication of MOSS in a third crop | Seed majors have a documented pattern of acquiring platform-stage gene-editing companies once core IP is de-risked |
What compounding looks like. The flywheel in a platform like MOSS is data and IP. Each crop in which homoplasmy is demonstrated extends the patent estate, increases the credibility of the platform claim, and strengthens the negotiating position with the next seed-industry counterparty. Each licensee relationship generates field data that informs which traits work where, which in turn guides the next round of platform development. The early signal that this flywheel has started would be a second crop demonstration beyond the two already reported and a first named industry partner [AgTechNavigator, March 2026].
The size of the win. A credible comparable for a successful CRISPR crop-trait platform is the private valuation arc of Inari Agriculture, which has raised at multi-billion-dollar valuations in successive private rounds, and the acquisition prices paid historically by seed majors for trait platforms (typically in the high hundreds of millions of dollars for de-risked but pre-blockbuster assets). Translating that to Cytotrait is a scenario, not a forecast: in the platform-licensor scenario above, a Series B valuation in the low-to-mid hundreds of millions of dollars is consistent with comparable CRISPR trait platforms at equivalent technical milestones (scenario, not a forecast). The ceiling case, in which MOSS becomes the de facto organelle-editing standard and is acquired by a seed major, plausibly clears the high-hundreds-of-millions threshold; the floor case, in which the technology works but only in dicots, looks more like a specialty trait company exit in the tens to low hundreds of millions (scenario, not a forecast).
Data Accuracy: YELLOW -- Scenarios are framed against confirmed Cytotrait facts and category comparables; specific valuation translations are explicitly labelled as scenarios rather than forecasts.
Sources
PUBLIC
[Preqin] Cytotrait Ltd. Asset Profile | https://www.preqin.com/data/profile/asset/cytotrait-ltd-/792424
[Cytotrait] Terms of Use and Privacy Policy | https://www.cytotrait.com/terms-of-use-and-privacy-policy
[AgTechNavigator, March 2026] Cytotrait claims breakthrough for ultra-high trait expression as it closes £3M seed round | https://www.agtechnavigator.com/Article/2026/03/10/cytotrait-claims-breakthrough-for-ultrahigh-trait-expression-as-it-closes-3m-seed-round/
[University of Manchester] Biotechnology spinout Cytotrait secures £3M seed funding to address global food security and sustainable agriculture | https://www.manchester.ac.uk/about/news/biotechnology-spinout-cytotrait-secures-seed-funding/
[Tech Funding News] Cytotrait bags £3M to bring organelle engineering to wheat, maize and potato farms | https://techfundingnews.com/manchester-spinout-cytotrait-bags-3m-to-build-more-resilient-crops/
[iGrow News, 2026] Cytotrait Secures $4M to Advance MOSS Crop Technology | https://igrownews.com/cytotrait-latest-news/
[Pulse 2.0] Cytotrait: £3 Million Seed Funding Raised For Crop Engineering Technology | https://pulse2.com/cytotrait-3-million-seed-funding-raised-for-crop-engineering-technology/
[International Biopharmaceutical Industry] Cytotrait secures £3M seed funding to address global food security and sustainable agriculture | https://international-biopharma.com/cytotrait-secures-3m-seed-funding-to-address-global-food-security-and-sustainable-agriculture/
[Prolific North] Northern Gritstone leads £3m seed fund for Manchester Uni biotech spinout | https://www.prolificnorth.co.uk/news/northern-gritstone-leads-3m-seedfund-for-manchester-uni-biotech-spinout/
[The Bae HQ, March 2026] Cytotrait Raises £3M to Apply Its Organelle-Targeting MOSS Platform to Wheat, Maize, Potato and Canola | https://www.thebaehq.com/news/cytotrait-raises-3m-northern-gritstone-crop-engineering-moss
[Tech.eu, March 2026] Cytotrait raises £3M for agricultural gene-editing technology | https://tech.eu/2026/03/09/cytotrait-raises-ps3m-for-agricultural-gene-editing-technology/
[University of Manchester Innovation Factory] Cytotrait secures £3M seed funding to address global food security and sustainable agriculture | https://www.uominnovationfactory.com/news/cytotrait/
[Business Live] £3m seed funding for crop biotech firm Cytotrait | https://www.business-live.co.uk/technology/3m-seed-funding-crop-biotech-33559827
[Startupmag] Cytotrait secures £3m seed to boost yields via chloroplast and mitochondrial edits | https://www.startupmag.co.uk/funding/cytotrait-2026-seed-funding/
Articles about Cytotrait Ltd.
- Cytotrait Is Betting Edited Chloroplasts Can Lift Yields in Wheat, Maize and Potato — A Manchester spinout raised £3M to push its MOSS platform from two demonstrated crops into the staples that feed most of the planet.